Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Early diagnosis of frontal fibrosing alopecia is crucial to prevent permanent hair loss.

This review emphasizes the importance of accurately distinguishing between diffuse alopecia areata and telogen effluvium in dermatological practice due to differing treatment implications and long-term patient expectations, but reports no new clinical results.

This study found that oral tofacitinib led to clinically significant improvement in alopecia areata severity scores among pre-adolescents, though results varied and further evaluation in clinical trials is needed.

This paper presents two cases of frontal fibrosing alopecia in postmenopausal women, noting challenges in monitoring due to the invasive nature of the diagnostic process.

In this case report, the authors describe a rare presentation of alopecia areata mimicking frontal fibrosing alopecia, emphasizing the diagnostic value of trichoscopy and the need to consider alopecia areata in differential diagnoses.

Oral and topical tofacitinib can effectively treat severe hair loss with minimal side effects.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

In this retrospective analysis, the authors reported that off-label tofacitinib treatment in 35 alopecia areata patients demonstrated safety, with no serious adverse events, and effectiveness, with 83.9% showing significant scalp regrowth and 32.3% achieving near total or total regrowth.

This study found that line-field confocal optical coherence tomography effectively visualized microscopic alterations in alopecia areata, suggesting its potential use in diagnosis and monitoring.

Early stage bald spots are linked to skin inflammation and damage to the upper part of the hair follicle.

This study found that among adults with severe alopecia areata, alopecia totalis, or alopecia universalis, oral tofacitinib was more effective than methotrexate in reducing hair loss over a 12-week period, though long-term safety and efficacy remain unestablished.

This study observed that fibrosing alopecia in a pattern distribution shows varied histological features and may resemble lichen planopilaris with initial diffuse distribution, potentially leading to scarring alopecia.

This study reports that anifrolumab showed promising improvement in a case of refractory discoid lupus erythematosus, specifically enhancing skin lesions and promoting hair regrowth, suggesting potential as an effective therapy for severe cases.

This review discusses the etiology, pathogenesis, clinical presentation, and treatment of frontal fibrosing alopecia, noting the lack of clinical trial data and limited observational treatment results.

This pilot study found that examining changes in scalp scales after scraping may effectively distinguish seborrheic dermatitis associated with androgenetic alopecia from fibrosing alopecia in a pattern distribution.

This study found that topical fluridil increased the anagen hair percentage in men with androgenetic alopecia without causing irritation or systemic absorption over 9 months.

This study explored the experiences of systemic lupus erythematosus patients receiving Anifrolumab, revealing improvements in self-reported symptoms and daily life impacts alongside decreased disease activity and lowered corticosteroid use.

The researchers reported that treating Alopecia Areata patients with the homeopathic remedy Fluoric Acid resulted in substantial hair regrowth and reduced relapse rates over a 6-year period, suggesting it may be an effective alternative to conventional treatments.

This study found that intramuscular triamcinolone acetonide may be an effective and safe treatment option for managing refractory alopecia areata, showing a 63% response rate in patients and hair regrowth negatively correlated with initial scalp involvement.

This review discusses frontal fibrosing alopecia, noting its clinical characteristics, possible environmental factors, and lack of evidence-based therapies, but reports no new research findings.

This study found that targeting androgen receptors with prostate cancer drugs ARN509 and finasteride induced remission and increased survival in a leukemia mouse model, suggesting a potential new treatment approach for acute myeloid leukemia.

This review discusses the pathogenesis and clinical features of androgenetic alopecia, highlighting potential links to fibrosing alopecia and suggesting the need for combined therapeutic approaches; it reports no new clinical results.

This review discusses frontal fibrosing alopecia in males and reports no new clinical results, indicating a broader demographic affected by this inflammatory disorder beyond postmenopausal women.

In this study, oral tofacitinib showed higher efficacy and tolerability in treating refractory alopecia totalis and universalis compared to traditional treatments, achieving a 50% improvement in severity scores for 44.4% of patients over six months, with fewer adverse effects.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

This study found that tofacitinib was well tolerated and led to clinical improvement in 77% of potential responders with severe alopecia areata, alopecia totalis, or alopecia universalis.

In this review, cosmetic practices such as non-ablative lasers, autologous fat injections, and oral isotretinoin may help alleviate certain symptoms of frontal fibrosing alopecia, while treatments like deep chemical peels and ablative laser therapies are contraindicated due to potential scarring risks.

FFA in men shows unique features and treatment results vary widely.

This study discovered that adipose tissue infiltration at the isthmus level appears significantly more often in frontal fibrosing alopecia cases compared to controls, suggesting a potential role in the condition's pathology.

This study suggests that oral tofacitinib may be an effective treatment for beard regrowth in men with alopecia areata of the beard, with a strong correlation observed between beard and scalp hair regrowth.